Author

C. Kumar-Sinha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. Shi· 2 shared L. Wang· 2 shared A. A. Alaniz· 1 shared A. Goodrum· 1 shared A. M. Chinnaiyan· 1 shared A. Xu· 1 shared B. Magnuson· 1 shared C. M. Julian· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Shi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1

Q. Deng, R. Natesan, F. Cidre-Aranaz, S. Arif, Y. Liu, R. Rasool, P. Wang, Z. Cramer, M. Chou, C. Kumar-Sinha, K. Weber, K. Eisinger-Mathason, N. Grillet, T. G. P. Grunewald, i. a. asangani

The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.

bioRxiv · Feb 22, 2021Cancer Biology

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways

L. M. Maurer, R. E. Venier, E. Mukherjee, C. M. Julian, J. D. Daley, N. G. Bailey, M. F. Jacobs, C. Kumar-Sinha, H. Raphel, K. Weiss, K. A. Janeway, R. Mody, P. C. Lucas, L. M. McAllister-Lucas, K. M. Bailey

This study shows that Ewing sarcoma cells with germline BARD1 mutations are sensitive to PARP inhibitors and that PARP inhibition increases PD-L1 expression, suggesting potential for combination immunotherapy.

bioRxiv · Sep 18, 2020 · PreprintCancer Biology

An Essential Role for Argonaute 2 in EGFR-KRAS Signaling in Pancreatic Cancer Development

S. Shankar, J. Tien, R. F. Siebenaler, S. Chugh, V. L. Dommeti, S. Zelenka-Wang, J. Waninger, K. M. Juckette, A. Xu, X.-M. Wang, M. Mody, S. Eyunni, A. Goodrum, G. Tsaloff, Y. Zhang, , A. M. Chinnaiyan

This study shows AGO2 is required for pancreatic cancer progression but not initiation, with its role dependent on mutant KRAS and EGFR signaling.

bioRxiv · Aug 1, 2019Cancer Biology

HNF1A is a Novel Oncogene and Central Regulator of Pancreatic Cancer Stem Cells

E. Abel, M. Goto, B. Magnuson, S. Abraham, N. Ramanathan, E. Hotaling, A. A. Alaniz, C. Kumar-Sinha, M. L. Dziubinski, S. Urs, L. Wang, J. Shi, M. Waghray, M. Ljungman, H. C. Crawford, D. M. Simeone

This study identifies HNF1A as a central regulator of pancreatic cancer stem cells and a novel oncogene in pancreatic ductal adenocarcinoma.

bioRxiv · Dec 22, 2017Cancer Biology